Drugs / (Autologous Adipose-derived Mesenchymal Stem Cells)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04612465 | Jan 2020 → Apr 2025 overdue | intestinal fistula | Anterogen Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (Autologous Adipose-derived Mesenchymal Stem Cells) | “ASC(Autologous Adipose-derived Mesenchymal Stem Cells)” NCT04612465 ↗ |
| Known as | ASC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04612465 ↗ |
| Modality | Cell therapy | “(Autologous Adipose-derived Mesenchymal Stem Cells)” NCT04612465 ↗ |